Premium Company Profile Medarex

Medarex is a research-oriented biopharmaceutical company focused on human therapeutic antibody development. While the company has yet to generate meaningful revenue from direct product sales, it is approaching late-stage R&D milestones in several high prevalence disease states: melanoma, certain solid tumors (renal, ovarian, prostate), and rheumatoid arthritis (& other autoimmune diseases).

Report Highlights
Medarex discovers, develops, and commercializes human antibody-based therapeutic products to treat cancer, inflammation, autoimmune disorders, and infectious diseases. The company applies its UltiMAb Human Antibody Development System, and product development and clinical manufacturing technologies to generate, support, and commercialize a range of fully human antibody product candidates for itself and its partners. The company has partnership and/or collaboration agreements principally with Amgen, Bristol-Myers Squibb; Centocor; Eli Lilly and Company; Genmab; ImClone Systems; MedImmune; Novartis Pharma; Novo Nordisk; Pfizer; and Kirin Brewing Co.
[Studien Infos ausblenden]

Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Locations and Subsidiaries 12
Company Financials 13
Overview 13
Business Segment Performance 19
Products & Services 20
Product Description 20
AC Forecast Product Sales 23
Competitors and Strategic Business Relationships 25
Top Competitors 25
Key Suppliers 26
Key Clients 26
Shareholding Structure 28
Strategy 29
Company View 29
Strategy 30
SWOT Analysis 32
Overview 32
Strengths 33
Weaknesses 34
Opportunities 35
Threats 36
Value Chain Analysis 37
Overview 37
Discovery and Product Development 37
Manufacturing 38
Scorecard 39
Overview 39
Scorecard Analysis 39
Key Employees 41
List of Key Employees 41
Key Employee Biographies 42
Financial and Operational Overview 47
APPENDIX 49
Ask the analyst 49
Datamonitor consulting 49
Disclaimer 49
[Inhaltsverzeichnis ausblenden]

Table 1: Medarex - Key Facts 6
Table 2: Medarex - Other Locations and Subsidiaries 12
Table 3: Medarex - Year-End Share Price and Market Capitalization, 2002-2006 ($) 13
Table 4: Medarex - Key Events Impacting Share Price Performance 14
Table 5: Medarex - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 15
Table 6: Medarex - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 17
Table 7: Medarex - Balance Sheet, 2002-2006 ($ Mn) 18
Table 8: Medarex - Cash Flow, 2002-2006 ($ Mn) 18
Table 9: Medarex - Revenue Breakdown, 2002-2006 ($ Mn) 19
Table 10: Medarex - In-house Pipeline Products 20
Table 11: Medarex - Collaboration Pipeline Products 21
Table 12: Medarex - Forecast Sales, 2006-2010 ($ Mn) 23
Table 13: Medarex – Top Competitors 26
Table 14: Medarex - Key Clients 27
Table 15: Medarex - Key Shareholders 28
Table 16: Medarex - SWOT Analysis Summary 32
Table 17: Medarex – Value Chain Analysis 37
Table 18: Medarex - Scorecard 39
Table 19: Medarex - Key Employees 41
Table 20: Medarex - Financial and Operational Overview 47

Figure 1: Medarex - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 16
Figure 2: Medarex - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 17
Figure 3: Medarex - Key Strategic Revenues, 2006-2010 ($ Mn) 24
[Tabellenverzeichnis ausblenden]